A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese

Inclusion Criteria: * A signed and dated informed consent form obtained from the subject before any study related procedures take place. * Age ≥18 years to ≤65 years at Visit 1. * The subject has a new diagnosis of type 2 diabetes without any treatment. * HbA1c ≥8.0% to ≤14.0% at Visit 1. * BMI(Body Mass Index)≥24kg/m2 to ≤40kg/m2 at Visit 1. Exclusion Criteria: * The subject has a history of type 1 diabetes or a secondary form of diabetes. * The subject has received an anti-diabetic drug before the screening visit. * Treatment with systemic steroids 2 months prior to screening * Treatment with anti-obesity drug 2 months prior to screening or any other treatment at the time of screening(i.e. surgery etc) leading to unstable body weight. * The subject has a history of acute or chronic pancreatitis * Any gastrointestinal diseases or surgeries that induce chronic malabsorption * Cancer and medical history of cancer(except basal cell skin cancer or squamous cell skin cancer). * The subject has a history of recurrent severe hypoglycaemia. * Cardiovascular disease,within the last 6months prior to screening,defined as: stroke;decompensated heart failure New York Heart Association(NYHA) class III or IV;Myocardial infarction;unstable angina pectoris;or coronary bypass graft or angioplasty. * Uncontrolled treated/untreated severe hypertension (systolic blood pressure ≥180 millimetre(mm) mercury(Hg) and/or diastolic blood pressure ≥100 millimetre(mm) mercury(Hg). * Impaired liver fun…